167 related articles for article (PubMed ID: 7753615)
1. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
3. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
[TBL] [Abstract][Full Text] [Related]
4. Parvovirus B19 antibodies in patients with haemophilia A.
Peerlinck K; Goubau P; Reybrouck R; Desmyter J; Vermylen J
Thromb Haemost; 1995 Mar; 73(3):555-6. PubMed ID: 7667846
[No Abstract] [Full Text] [Related]
5. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
6. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
8. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
[TBL] [Abstract][Full Text] [Related]
9. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
10. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
[TBL] [Abstract][Full Text] [Related]
11. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
[TBL] [Abstract][Full Text] [Related]
12. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
Yee TT; Cohen BJ; Pasi KJ; Lee CA
Br J Haematol; 1996 May; 93(2):457-9. PubMed ID: 8639448
[TBL] [Abstract][Full Text] [Related]
13. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.
Flores G; Juárez JC; Montoro JB; Tusell JM; Altisent C; Juste C; Jardí R
Haemophilia; 1995 Apr; 1(2):115-7. PubMed ID: 27214319
[TBL] [Abstract][Full Text] [Related]
15. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
Lefrère JJ; Mariotti M; Thauvin M
Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
17. Human parvovirus B19 infection in persons with haemophilia.
Prowse C; Dow B; Pelly SJ; McIntosh E; Reading S; Lowe GD; Gibson B; Cachia P; Thomas A; Dennis R; Ludlam CA
Thromb Haemost; 1998 Aug; 80(2):351. PubMed ID: 9716173
[No Abstract] [Full Text] [Related]
18. B19 parvovirus withstands "super heating" in antihemophilic concentrates.
Morfini M; Azzi A; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):821. PubMed ID: 8950802
[No Abstract] [Full Text] [Related]
19. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
20. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products.
Lefrère JJ; Mariotti M
Cell Mol Biol (Noisy-le-grand); 1995 Nov; 41(7):985-8. PubMed ID: 8595378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
